Beacon: A Phase II Study of Bevacizumab, Atezolizumab, and Cobimetinib in Patients with Recurrent, Platinum Resistant, High Grade Serous Ovarian Cancer.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined